LORATADINÃ LEK 5mg/5ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

loratadinã lek 5mg/5ml

lek pharmaceuticals d.d. - slovenia - loratadinum - susp. orala - 5mg/5ml - antihistaminice de uz sistemic alte antihistaminice de uz sistemic

FIBRYGA 1 g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fibryga 1 g

octapharma pharmazeutika produktionsges m.b.h. - austria - fibrinogen uman - pulb.+solv. pt. sol. inj./perf. - 1g - vitamina k si alte hemostatice fibrinogen

HAEMOCOMPLETTAN P 1 g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemocomplettan p 1 g

csl behring gmbh - germania - fibrinogen uman - pulb. pt. sol. inj./perf. - 1g - vitamina k si alte hemostatice fibrinogen

Egocin Л.А. Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

egocin Л.А.

krka, Словения - oxitetraciclină dihidrat - крупного рогатого скота, овец, коз, свиней, iepuri, păsări

Celexium România - română - myHealthbox

celexium

bayer ag - granule dispersabile în apă, de culoare bej si albe (wg) - florasulam 105.0 g/kg + metsulfuron metil 82.8 g/kg + tribenuron metil 83.0 g/kg

Breyanzi Uniunea Europeană - română - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenți antineoplazici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Imcivree Uniunea Europeană - română - EMA (European Medicines Agency)

imcivree

rhythm pharmaceuticals netherlands b.v. - setmelanotide - obezitatea - preparate antiobezitate, excl. produse alimentare - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.